Cyclerion Therapeutics Inc Asset Resilience Ratio
Cyclerion Therapeutics Inc asset resilience ratio. Cyclerion Therapeutics Inc (CYCN) has an Asset Resilience Ratio of 0.00% as of March 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cyclerion Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cyclerion Therapeutics Inc (2016–2018)
Asset resilience ratio of Cyclerion Therapeutics Inc from 2016 to 2018. This chart shows how Cyclerion Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Cyclerion Therapeutics Inc (CYCN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cyclerion Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cyclerion Therapeutics Inc (CYCN) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cyclerion Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cyclerion Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Cyclerion Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Cyclerion Therapeutics Inc Asset Resilience Ratio by Year (2016–2018)
Cyclerion Therapeutics Inc asset resilience ratio by year from 2016 to 2018. The table below shows the annual Asset Resilience Ratio data for Cyclerion Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $7.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $5.47 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $3.88 Million | -- |
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more